Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm's goal is to consolidate resources to enhance it's prescription drug pipeline, maximize Crestor (rosuvastatin) product value, and strengthen domestic marketing and overseas expansion.
You may also be interested in...
Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
The U.S. subsidiary of Shionogi acquired global development and marketing rights to QuatRx Pharmaceuticals' selective estrogen receptor modulator ospemifene, building on the company's sexual medicine and women's health portfolio
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.